Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|September 1, 2020

J&J to Supply the Government of Canada with Doses of its COVID-19 Vaccine Candidate

Negotiations for a final advance purchase agreement where the Government of Canada purchases the vaccine candidate on a not-for-profit basis for emergency pandemic use are underway.

Janssen Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced on Aug. 31, 2020 that it will supply the Government of Canada with 38 million doses of its SARS-CoV-2 vaccine candidate, Ad26.COV2.S.

According to a company press release, negotiations for a final advance purchase agreement in which the Government of Canada purchases the vaccine candidate on a not-for-profit basis for emergency pandemic use are underway.

The vaccine candidate is currently involved in a Phase I/IIa first-in-human clinical trial for healthy volunteers in the United States and Belgium, the press release said. A Phase III trial will also be executed based on interim data from the Phase I/IIa trials and the approval of regulators.

“We are deeply committed to providing global access to our SARS-CoV-2 vaccine candidate. As we proceed with development of our vaccine, we are simultaneously working with partners around the world, including the Government of Canada, to ensure our vaccine is made available to citizens globally, if proven to be safe and effective,” said Paul Stoffels, MD, vice-chairman of the Executive Committee and chief scientific officer, Johnson & Johnson, in the press release.

Source: Johnson & Johnson


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.